Ayouba Ahidjo, Thaurignac Guillaume, Morquin D., Tuaillon E., Raulino R., Nkuba A., Lacroix Audrey, Vidal Nicole, Foulongne V., Le Moing V., Reynes J., Delaporte E., Peeters Martine. (2020). Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. Journal of Clinical Virology, 129, p. art. 104521 [6p.]. ISSN 1386-6532.
Titre du document
Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV
Année de publication
2020
Auteurs
Ayouba Ahidjo, Thaurignac Guillaume, Morquin D., Tuaillon E., Raulino R., Nkuba A., Lacroix Audrey, Vidal Nicole, Foulongne V., Le Moing V., Reynes J., Delaporte E., Peeters Martine
Source
Journal of Clinical Virology, 2020,
129, p. art. 104521 [6p.] ISSN 1386-6532
Background: Knowledge of the COVID-19 epidemic extent and the level of herd immunity is urgently needed to help manage this pandemic. Methods: We used a panel of 167 samples (77 pre-epidemic and 90 COVID-19 seroconverters) and SARS-CoV1, SARS-CoV2 and MERS-CoV Spike and/or Nucleopcapsid (NC) proteins to develop a high throughput multiplex screening assay to detect IgG antibodies in human plasma. Assay performances were determined by ROC curves analysis. A subset of the COVID-19+ samples (n= 36) were also tested by a commercial NC-based ELISA test and the results compared with those of the novel assay. Results: On samples collected >= 14 days after symptoms onset, the accuracy of the assay is 100 % (95 % CI: 100-100) for the Spike antigen and 99.9 % (95 % CI:99.7-100) for NC. By logistic regression, we estimated that 50 % of the patients have seroconverted at 5.7 +/- 1.6; 5.7 +/- 1.8 and 7.9 +/- 1.0 days after symptoms onset against Spike, NC or both antigens, respectively and all have seroconverted two weeks after symptoms onset. IgG titration in a subset of samples showed that early phase samples present lower IgG titers than those from later phase. IgG to SARS-CoV2 NC cross-reacted at 100 % with SARS-CoV1 NC. Twenty-nine of the 36 (80.5 %) samples tested were positive by the commercial ELISA while 31/36 (86.1 %) were positive by the novel assay. Conclusions: Our assay is highly sensitive and specific for the detection of IgG antibodies to SARS-CoV2 proteins, suitable for high throughput epidemiological surveys. The novel assay is more sensitive than a commercial ELISA.
Plan de classement
Santé : généralités [050]
;
Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
FRANCE
Localisation
Fonds IRD [F B010079419]
Identifiant IRD
fdi:010079419
